Progress in Clinical Pharmacology in China: An Ongoing Evolution

Clinical Pharmacology & Therapeutics, vol. 117, pp. 609–611

Abstract

The landscape of clinical pharmacology research in China has continued to evolve in 2024, shown by research advancements in physiologically based pharmacokinetics (PBPK), regulatory science, and a growing emphasis on precision medicine (Figure 1).In this editorial, we reflect on the progress achieved since the Clinical Pharmacology & Therapeutics (CPT) editorial on China in early 2024, 1 showcase key research contributions, and envision a path forward for continued innovation and advancement.

Authors 2

1. Liang Yu Zhao corresponding

   University of California, San Francisco

   Affiliation as printed

   Department of Bioengineering and Therapeutic Sciences, School of Pharmacy and Medicine University of California San Francisco California USA

   Department of Bioengineering and Therapeutic Sciences, School of Pharmacy and Medicine, University of California, San Francisco, California, USA

2. Piet H. van der Graaf Aachen

   Leiden University

   Affiliation as printed

   Certara Canterbury UK

   University of Leiden Leiden The Netherlands

   Certara, Canterbury, UK

   University of Leiden, Leiden, The Netherlands